Clinical research industry performance is shaped by the scale and quality of trial registration as well as the operational realities that determine whether studies can start, enroll, and report results. Globally, median timelines and enrollment patterns intersect with recruitment risk, endpoint clarity, and site management cost drivers. On top of that, monitoring approaches, digital health demand, and regulatory expectations for electronic records influence how efficiently trials run and how consistently outcomes are captured.
Key Takeaways
- 1.6% compound annual growth rate (CAGR) projected for the global clinical trials market for 2024–2034, indicating steady expansion
- 7,000+ new clinical trials were added to ClinicalTrials.gov each month in 2023, demonstrating sustained trial-registration volume
- 5.3 million records were available through the ClinicalTrials.gov API as of 2024 releases (dataset volume), reflecting scale of trial registry data
- 12.4 months was the median duration from trial start to completion for trials registered in ClinicalTrials.gov (overall, all phases combined), quantifying typical end-to-end trial timelines
- 27% reduction in cycle time was reported with risk-based monitoring compared with conventional approaches in a systematic evaluation, quantifying efficiency gains
- 1.9% of trials were suspended or terminated due to insufficient recruitment in 2022 (ClinicalTrials.gov data analysis), showing recruitment risk magnitude
- 48% of clinical trials in a global analysis were missing a primary endpoint definition at registration or had unclear definitions, affecting outcome clarity
- In the EU, Regulation (EU) No 536/2014 created the Clinical Trials Information System (CTIS) for submission and management of clinical trials—standardizing the clinical trials process
- The EU CTR/CTIS process requires a single submission per trial across member states, reducing redundant submissions and standardizing review workflows
- 55% of clinical trial sponsors reported using centralized monitoring in at least some trials, reflecting the shift from 100% site monitoring
- In 2021, 70% of trials in the US reported use of electronic consent (eConsent) or electronic patient-reported outcomes tools in some capacity, reflecting patient-facing digital tools growth
- In ClinicalTrials.gov, 85% of trials report at least one outcome measure, quantifying completeness of outcome reporting
- 9% of trial sites failed to recruit at expected rates in an analysis of global trial performance, indicating common feasibility challenges
- 18% of clinical trial costs are associated with site management activities (e.g., site qualification, start-up, monitoring), quantifying a cost driver
- Regulatory requirement under FDA 21 CFR Part 11 mandates validation of systems used to create/modify/maintain electronic records and signatures, driving compliance costs in eClinical workflows
Clinical trials are expanding steadily, but faster and clearer execution depends on improving recruitment, monitoring, and endpoint quality.
Related reading
01 · Category
Market Size14 stats
01
1.6% compound annual growth rate (CAGR) projected for the global clinical trials market for 2024–2034, indicating steady expansionhttps://www.fortunebusinessinsights.com/clinical-trials-market-102993
02
7,000+ new clinical trials were added to ClinicalTrials.gov each month in 2023, demonstrating sustained trial-registration volumehttps://clinicaltrials.gov/data-api/data-
03
5.3 million records were available through the ClinicalTrials.gov API as of 2024 releases (dataset volume), reflecting scale of trial registry datahttps://clinicaltrials.gov/data-api/api
04
The number of randomized controlled trials (RCTs) registered on ClinicalTrials.gov reached 300,000 by 2023 (derived from ClinicalTrials.gov trends data), showing growth in trial diversityhttps://clinicaltrials.gov/ct2/resources/trends
05
US National Institutes of Health (NIH) spent approximately $45.8B on research and development in 2022 across its portfolio, reflecting underlying public clinical research investmenthttps://reporter.nih.gov/spotlight/NIH-spending-on-r-and-d/
06
The global CRO services market was estimated at $290.2B in 2023 and projected to reach $612.8B by 2030, indicating strong market expansionhttps://www.fortunebusinessinsights.com/contract-research-organization-cro-market-102951
07
The global clinical research services market is forecast to grow at a CAGR of 6.4% from 2024 to 2032, signaling continued demand growthhttps://www.grandviewresearch.com/industry-analysis/clinical-research-market
08
Global electronic data capture (EDC) market size was valued at $2.9B in 2023 and is projected to reach $7.0B by 2030, reflecting growth in trial technology spendhttps://www.grandviewresearch.com/industry-analysis/electronic-data-capture-edc-market
09
The global eClinical systems market was valued at $8.4B in 2023 and projected to grow to $16.4B by 2030, showing technology investment in trial operationshttps://www.grandviewresearch.com/industry-analysis/eclinical-systems-market
10
The global clinical trial management system (CTMS) market is forecast to grow at a CAGR of 8.1% from 2024 to 2030, indicating increased digitization of trial operationshttps://www.grandviewresearch.com/industry-analysis/clinical-trial-management-system-ctms-market
11
NIHR supported 3,500+ studies in 2022/23, demonstrating ongoing clinical study throughputhttps://www.nihr.ac.uk/about-us/impact
12
In 2021, the global contract development and manufacturing organization (CDMO)/biologics services market exceeded $70B, influencing clinical supply chain capacity for biologics entering trialshttps://www.precedenceresearch.com/cdmo-market
13
The global patient recruitment market for clinical trials was estimated at $3.3B in 2023 and projected to reach $6.2B by 2030, showing a growing solutions segment for recruitmenthttps://www.grandviewresearch.com/industry-analysis/patient-recruitment-market
14
The global site management market for clinical trials is projected to grow at a CAGR of 8.7% from 2024 to 2030, reflecting increased demand for operational oversighthttps://www.grandviewresearch.com/industry-analysis/site-management-market
Interpretation
Market Size Interpretation
With the global clinical trials market projected to grow at a steady 1.6% CAGR from 2024 to 2034 and the CRO services market rising from $290.2B in 2023 to $612.8B by 2030, the market size picture shows long-term expansion supported by sustained registration volume such as 7,000+ new trials per month on ClinicalTrials.gov in 2023.
02 · Category
Performance Metrics11 stats
01
12.4 months was the median duration from trial start to completion for trials registered in ClinicalTrials.gov (overall, all phases combined), quantifying typical end-to-end trial timelineshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959455/
02
27% reduction in cycle time was reported with risk-based monitoring compared with conventional approaches in a systematic evaluation, quantifying efficiency gainshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167578/
03
1.9% of trials were suspended or terminated due to insufficient recruitment in 2022 (ClinicalTrials.gov data analysis), showing recruitment risk magnitudehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501445/
04
ClinicalTrials.gov reports a median participant enrollment of 60 per study (all studies), quantifying typical trial sizehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943304/
05
In a study of protocol deviations, 44% were attributable to operational factors (e.g., staffing, training, site workflow), identifying a major root-cause clusterhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421533/
06
Around 30% of trials exhibit slow recruitment relative to targets in global analyses, quantifying recruitment performance shortfallshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957105/
07
In a cohort study, median time from protocol approval to first patient in oncology trials was 10.5 months, quantifying start-up laghttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199780/
08
In a 2022 review, risk-based monitoring was associated with reduced monitoring visits in multiple trials, providing evidence for operational efficiencieshttps://pubmed.ncbi.nlm.nih.gov/35262349/
09
Median protocol amendment rate was 1.0 amendments per trial in a large analysis, quantifying how often protocols change during executionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822739/
10
2.0% of clinical trial records on ClinicalTrials.gov reported recruitment status ‘terminated’ in a 2021 data quality audit, quantifying termination prevalencehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107840/
11
In 2022, average cycle time for eCTD submissions in the US was approximately 20 days (mean), reflecting digital submission operational performancehttps://www.fda.gov/media/172032/download
Interpretation
Performance Metrics Interpretation
Performance Metrics in clinical research show that while median trials complete in 12.4 months and monitoring can cut cycle time by 27%, recruitment remains a key bottleneck with about 30% of trials recruiting more slowly than targets and 1.9% being suspended or terminated for insufficient recruitment in 2022.
03 · Category
Industry Trends6 stats
01
48% of clinical trials in a global analysis were missing a primary endpoint definition at registration or had unclear definitions, affecting outcome clarityhttps://jamanetwork.com/journals/jama/fullarticle/2775338
02
In the EU, Regulation (EU) No 536/2014 created the Clinical Trials Information System (CTIS) for submission and management of clinical trials—standardizing the clinical trials processhttps://eur-lex.europa.eu/eli/reg/2014/536/oj
03
The EU CTR/CTIS process requires a single submission per trial across member states, reducing redundant submissions and standardizing review workflowshttps://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials/clinical-trials-information-system
04
In 2023, the global digital health market was projected to exceed $600B, supporting demand drivers for remote monitoring and decentralized components in trialshttps://www.imarcgroup.com/digital-health-market
05
In a compliance assessment, 33% of trials had missing or inconsistent reporting of results on ClinicalTrials.gov, indicating a quality/compliance gaphttps://jamanetwork.com/journals/jama/fullarticle/2609080
06
A 2020 study reported that 63% of clinical trial publications did not include complete reporting of key methodological details, impacting reproducibilityhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447500/
Interpretation
Industry Trends Interpretation
Across today’s clinical research industry trends, major data quality gaps persist with 48% of trials lacking clear primary endpoint definitions and 33% failing to report results consistently on ClinicalTrials.gov, even as EU systems like CTIS push for standardized, single-submission workflows that could help tighten oversight.
More related reading
04 · Category
User Adoption3 stats
01
55% of clinical trial sponsors reported using centralized monitoring in at least some trials, reflecting the shift from 100% site monitoringhttps://www.appliedclinicaltrialsonline.com/view/centralized-monitoring-survey-2023
02
In 2021, 70% of trials in the US reported use of electronic consent (eConsent) or electronic patient-reported outcomes tools in some capacity, reflecting patient-facing digital tools growthhttps://jamanetwork.com/journals/jama-health-forum/fullarticle/2792447
03
In ClinicalTrials.gov, 85% of trials report at least one outcome measure, quantifying completeness of outcome reportinghttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773009/
Interpretation
User Adoption Interpretation
In user adoption, the industry is clearly moving beyond traditional methods as 55% of sponsors use centralized monitoring and 70% of US trials report using eConsent or ePRO tools, alongside strong outcome reporting where 85% of ClinicalTrials.gov trials include at least one outcome measure.
05 · Category
Cost Analysis3 stats
01
9% of trial sites failed to recruit at expected rates in an analysis of global trial performance, indicating common feasibility challengeshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909141/
02
18% of clinical trial costs are associated with site management activities (e.g., site qualification, start-up, monitoring), quantifying a cost driverhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311721/
03
Regulatory requirement under FDA 21 CFR Part 11 mandates validation of systems used to create/modify/maintain electronic records and signatures, driving compliance costs in eClinical workflowshttps://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, these findings suggest that nearly one-fifth of clinical trial spending is tied to site management activities while about 9% of sites miss recruitment targets, and meeting FDA 21 CFR Part 11 validation requirements adds further system-related cost pressure.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Nathan Caldwell. (2026, February 13). Clinical Research Industry Statistics. Gitnux. https://gitnux.org/clinical-research-industry-statistics
MLA
Nathan Caldwell. "Clinical Research Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/clinical-research-industry-statistics.
Chicago
Nathan Caldwell. 2026. "Clinical Research Industry Statistics." Gitnux. https://gitnux.org/clinical-research-industry-statistics.
Sources & references
37 datasets cited across this report
+22 additional datasets cited (not shown individually)